These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32530766)

  • 1. Reply to E. Paulino et al.
    Penson RT; Lowe ES
    J Clin Oncol; 2020 Aug; 38(23):2698. PubMed ID: 32530766
    [No Abstract]   [Full Text] [Related]  

  • 2. SOLO 3 Trial: How Do the Results Fit in With Current Evidence?
    Paulino E; Melo AC
    J Clin Oncol; 2020 Aug; 38(23):2697-2698. PubMed ID: 32530768
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to M.G. McNamara et al and M.S. Copur et al.
    Domchek SM; Kaufman B; Friedlander M
    J Clin Oncol; 2015 Aug; 33(23):2583-4. PubMed ID: 26124483
    [No Abstract]   [Full Text] [Related]  

  • 4. [POLO study].
    Hammel P
    Bull Cancer; 2019 Sep; 106(9):717-718. PubMed ID: 31420091
    [No Abstract]   [Full Text] [Related]  

  • 5. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
    Veeck J; Ropero S; Setien F; Gonzalez-Suarez E; Osorio A; Benitez J; Herman JG; Esteller M
    J Clin Oncol; 2010 Oct; 28(29):e563-4; author reply e565-6. PubMed ID: 20679605
    [No Abstract]   [Full Text] [Related]  

  • 6. Myelodysplastic Syndrome After Olaparib Treatment in Heavily Pretreated Ovarian Carcinoma.
    Sari M; Saip P
    Am J Ther; 2019; 26(5):e632-e633. PubMed ID: 30212381
    [No Abstract]   [Full Text] [Related]  

  • 7. Olaparib, a new hope for ovarian cancer.
    Samoon Z; Jabbar AA
    Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
    Saleh N; Copur MS
    Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365755
    [No Abstract]   [Full Text] [Related]  

  • 9. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
    J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
    Stewart J; George A; Banerjee S
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    Matulonis UA; Penson RT; Domchek SM; Kaufman B; Shapira-Frommer R; Audeh MW; Kaye S; Molife LR; Gelmon KA; Robertson JD; Mann H; Ho TW; Coleman RL
    Ann Oncol; 2016 Jun; 27(6):1013-1019. PubMed ID: 26961146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
    van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
    Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
    Vaclová T; Woods NT; Megías D; Gomez-Lopez S; Setién F; García Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Monteiro ANA; Benítez J; Osorio A
    Hum Mol Genet; 2016 Dec; 25(24):5287-5299. PubMed ID: 27742776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 17. PARP inhibitors plough on.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356598
    [No Abstract]   [Full Text] [Related]  

  • 18. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract]   [Full Text] [Related]  

  • 19. Olaparib shows promise in multiple tumor types.
    Cancer Discov; 2013 Jul; 3(7):OF5. PubMed ID: 23847380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of Cediranib-Olaparib Combo Revealed.
    Cancer Discov; 2019 Aug; 9(8):990-991. PubMed ID: 31182430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.